Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Mometasone/indacaterol demonstrates similar efficacy in men and women: pooled analyses of PALLADIUM and IRIDIUM studies Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Factors associated with exacerbations in patients with COPD: NOVELTY study Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
Does overprescribing antibiotics (abx) put patients (pts) at risk? A two part retrospective study Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009
Number needed to treat (NNT) with budesonide/formoterol to avoid one COPD exacerbation, with cost analysis of treatment Source: Eur Respir J 2004; 24: Suppl. 48, 540s Year: 2004
Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Analysis of the cases with haemoptysis in hospitalized patients (3 years retrospective study) Source: Eur Respir J 2001; 18: Suppl. 33, 379s Year: 2001
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Evolution in the prescription of the therapy combined with ICS-LABA in COPD: TRACE STUDY Source: International Congress 2017 – Markers of COPD progression Year: 2017
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021
ICS and risk of pneumonia in Swedish COPD patients: The ARCTIC study Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016
Late Breaking Abstract - Tocilizumab administration for the treatment of hospitalised patients with COVID-19: A systematic review and meta-analysis Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021